Generate Biomedicines
- Market cap
- 1.74B
- P/E (TTM)i
- -6.48
- P/Bi
- 3.82
- EPSi
- -1.96
- Div yieldi
- 0.00%
- 52W posi
- 22%
Anonymous reader poll. Unscientific, not investment advice.
Shares of Generate Biomedicines closed at 13.57, down 1.67%. At current prices, the business is worth about 1.74B, the #2875 most valuable US-listed company we track. Wall Street's 3-analyst consensus lands on Buy, with a price target averaging 26.00 (+92% from here). Against a 52-week band of 11.00-22.67, the shares are currently 22% of the way up.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 year.
- Recent price momentum is -16.3% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 5.6% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 13.80
- Open
- 13.59
- Day range
- 13.35 - 13.99
- Avg price
- 13.67
- Volume
- 926.43K
- Turnover
- 12.66M
- Turnover ratei
- 1.53%
- Volume ratioi
- 0.82
- Amplitudei
- 4.60%
- 52-week rangei
- 11.00 - 22.67
Valuation
- P/Ei
- -6.93
- P/E (TTM)i
- -6.48
- P/Bi
- 3.82
- EPSi
- -1.96
- Book value / shi
- 3.55
- Net profit
- -251.31M
- Net assets
- 456.04M
Share structure
- Market cap
- 1.74B
- Float capi
- 820.30M
- Shares out
- 128.35M
- Float sharesi
- 60.45M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2026-02-27
40.1% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-13.67M net over the window
Short interest
- Shares short
- 7.18M
- % of floati
- 5.59%
- Days to coveri
- 7.24
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Generate Biomedicines (GENB)?
Generate Biomedicines last traded at 13.57. The quote on this page refreshes every few seconds while US markets are open.
What is Generate Biomedicines's market cap?
About 1.74B.
What is the P/E ratio of Generate Biomedicines?
The trailing twelve-month P/E is -6.48. The Valuation tab shows it against the stock's own five-year range.
Does Generate Biomedicines pay a dividend?
Generate Biomedicines does not currently pay a regular dividend.
Is Generate Biomedicines a buy according to analysts?
The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 26.00, which implies 91.6% upside from the current price. This is not investment advice.
What is Generate Biomedicines's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Generate Biomedicines a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-10-08 05:37:23 · For reference only, not investment advice and not tailored to your situation.